This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Peptides & Oligonucleotides
MRNA Therapeutics

Scaling up manufacturing when it’s needed most

Posted by on 16 March 2021
Share this article

Complex scale-up manufacturing capacity and experience have long been central to the manufacturing capabilities at Thermo Fisher Scientific, request for nucleotides and in vitro transcription enzymes, critical raw materials, to support mRNA therapeutics was unprecedented in size, scope, and delivery timeline. To meet the massive increase in raw material supply means enzymes and nucleotides needed to be manufactured at an appropriate scale simultaneously, rather than one by one, as is more common in traditional timelines. Powering this project was 4 key capabilities from Thermo Fisher:

  • Network of world-class manufacturing sites staffed with experienced scientists
  • Complete portfolio of reagents for mRNA synthesis in regulatory compliance
  • Ability to invest in manufacturing sites
  • Rapidly mobilize a dedicated project team

Learn how Thermo Fisher Scientific was able to meet the unprecedented need for raw material to support mRNA therapeutics while growing capacity to serve future partnership within the nucleic acid therapeutics. Download the full whitepaper by simply hitting the 'Download Now' link at the top of the page.

Share this article